1. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007;26(2):225-39.
2. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3(10):721-32.
3. Liberti MV, Locasale JW. The Warburg Effect: How Does it Benefit Cancer Cells? Trends Biochem Sci. 2016;41(3):211-8.
4. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029-33.
5. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883-99.
6. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860-7.
7. Polk DB, Peek RM Jr. Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer. 2010;10(6):403-14.
8. de Repentigny L. Pathogenic activity of Candida albicans. Recent Pat Antiinfect Drug Discov. 2006;1(1):87-97.
9. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329-60.
10. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331(6024):1565-70.
11. Schwabe RF, Jobin C. The microbiome and cancer. Nat Rev Cancer. 2013;13(11):800-12.
12. Zitvogel L, Galluzzi L, Viaud S, et al. Cancer and the gut microbiota: an unexpected link. Sci Transl Med. 2015;7(271):271ps1.
13. Nardone G, Rocco A, Malfertheiner P. Review article: Helicobacter pylori and MALT lymphoma. Aliment Pharmacol Ther. 2004;19(6):563-70.
14. Ohnishi K, Ochiai A, Niwa O. The role of Aspergillus flavus in hepatocellular carcinoma. Tohoku J Exp Med. 1986;148(3):287-8.
15. Ganapathy-Kanniappan S, Geschwind JF. Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol Cancer. 2013;12:152.
16. Nissim Hay. Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy? Nat Rev Cancer. 2016;16(10):635-49.
17. Duan W, Shen X, Lei J, et al. Hyperglycemia, inflammation, and oxidative stress: The "triangular relationship" that contributes to diabetic kidney disease. Free Radic Biol Med. 2021;172:275-93.
18. Chang SH, Wang CY, Tsai SP, et al. Diabetes and risk of hepatocellular carcinoma: a systematic review and meta-analysis. Liver Int. 2014;34(4):550-9.
19. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414(6865):813-20.
20. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107(9):1058-70.
21. Dong H, Li CM, Yang DD, et al. Enhanced tumor angiogenesis in obesity: mechanisms and therapeutic implications. Oncotarget. 2017;8(33):55444-55457.
22. Cao Y. Adipocytokines in obesity and cancer. J Endocrinol. 2014;220(2):T47-T59.
23. Kanwar JR, Kamalapuram SK, Kanwar RK. Targeting PI3K/Akt/mTOR Signaling Pathway in Anti-Cancer Drug Discovery. Curr Med Chem. 2015;22(11):1238-47.
24. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9(8):550-62.
25. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. CA Cancer J Clin. 2010;60(4):207-21.
26. Vigneri P, Frasca F, Sciacca L, et al. Diabetes and cancer. Endocr Relat Cancer. 2009;16(4):1103-23.
27. Tseng CH. Diabetes, prediabetes and cancer mortality: a meta-analysis of cohort studies. Diabetologia. 2014;57(11):2365-74.
28. Ryu TY, Park J, Scherer PE. Hyperglycemia as a risk factor for cancer progression. Diabetes Metab J. 2014;38(6):387-96.
29. Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J Nat Prod. 2020;83(3):770-803.
30. Cragg GM, Pezzuto JM. Natural products as a vital source for the discovery of cancer chemotherapeutic and chemopreventive agents. Med Princ Pract. 2016;25(Suppl 2):41-59.
31. Cragg GM, Newman DJ. Plants as a source of anti-cancer agents. J Ethnopharmacol. 2005;100(1-2):72-9.
32. Fulda S. Modulation of Apoptosis by Natural Products for Cancer Therapy. Planta Med. 2010;76(11):1075-9.
33. Wong RS. Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res. 2011;30:87.
34. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1(1):27-35. Reyes-Farias M, Carrasco-Pozo C. The Anti-Cancer Effect of Quercetin: The Evidence from Clinical Trials. Nutrients. 2019;11(11):2718.
36. Scalbert A, Manach C, Morand C, Remesy C, Jimenez L. Dietary polyphenols and the prevention of diseases. Crit Rev Food Sci Nutr. 2005;45(4):287-306.
37. Pan MH, Lai CS, Ho CT. Anti-inflammatory activity of natural dietary flavonoids. Food Funct. 2010;1(1):15-31.
38. Wilken R, Veena MS, Wang MB, Srivatsan ES. Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol Cancer. 2011;10:12.
39. Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 2013;15(1):195-218.
40. Borlinghaus J, Albrecht F, Gruhlke MC, Nwachukwu ID, Slusarenko AJ. Allicin: chemistry and biological properties. Molecules. 2014;19(8):12591-618.
41. Thomson M, Ali M. Garlic [Allium sativum]: a review of its potential use as an anti-cancer agent. Curr Cancer Drug Targets. 2003;3(1):67-81.
42. Yang CS, Wang X, Lu G, Picinich SC. Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat Rev Cancer. 2009;9(6):429-39.
43. Khan N, Afaq F, Mukhtar H. Cancer chemoprevention through dietary antioxidants: progress and promise. Antioxid Redox Signal. 2008;10(3):475-510.
44. Paul R, Prasad M, Sah NK. Anticancer Biology of Azadirachta indica L (Neem): A Mini Review. Cancer Biol Ther. 2011;12(6):467-76.
45. Kumar S, Sherwani MR, Kumar A, et al. (2013). Neem (Azadirachta indica) leaf extract inhibits growth of prostate cancer cells by inducing apoptosis and cell cycle arrest. Anticancer Agents Med Chem. 13(4), 562-572.
46. Efferth T, Dunstan H, Sauerbrey A, Miyachi H, Chitambar CR. The anti-malarial artesunate is also active against cancer. Int J Oncol. 2001;18(4):767-73.
47. Firenzuoli F, Gori L, Lombardo G, et al. The efficacy of artemisinin derivatives for the treatment of cancer: A systematic review of pre-clinical and clinical studies. Phytomedicine. 2018;50:10-19.
48. Gopalakrishnan L, Doriya K, Kumar DS. Moringa oleifera: A review on nutritive importance and its medicinal application. Food Sci Hum Wellness. 2016;5(2):49-56.
49. Stohs SJ, Hartman MJ. Review of the Safety and Efficacy of Moringa oleifera. Phytother Res. 2015;29(6):796-804.
50. Carpinella MC, Ferrayoli CG, Palacios SM. Antifungal synergistic effect of Melia azedarach L. fruit extract and essential oil on Fusarium verticillioides. J Food Prot. 2005;68(5):1078-84.
51. Al-Snafi AE. The pharmacological importance of Melia azedarach L. - A review. IOSR J Pharm. 2015;5(4):1-15.
52. Katzung BG. Basic & Clinical Pharmacology. 12th ed. New York: McGraw-Hill Medical; 2012.
53. Bayet-Robert M, Kwiatkowski F, Leheurteur M, et al. Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biol Ther. 2010;9(1):8-14.
54. Terry P, Terry JB, Wolk A. Fruit and vegetable consumption in the prevention of cancer: an update. J Intern Med. 2001;250(4):280-90.
55. Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer. 2014;14(5):342-57.
56. Grant WB. An ecologic study of dietary and solar ultraviolet-B links to breast carcinoma mortality rates. Cancer. 2002;94(1):272-81.
57. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer. 2007;7(9):684-700.
58. Yu Z, Li Y, Liu F. Vitamin D and Cancer. Adv Nutr. 2018;9(6):899-909.
59. Wang Z, Sun Y. Vitamin D and Cancer Prevention. Crit Rev Food Sci Nutr. 2017;57(10):2054-2065.
60. Krishnan AV, Feldman D. Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annu Rev Pharmacol Toxicol. 2011;51:311-36.
61. Bikle DD. Vitamin D metabolism, mechanism of action, and clinical applications. Chem Biol. 2014;21(3):319-29.
62. Wacker M, Holick MF. Sunlight and Vitamin D: A global perspective for health. Dermatoendocrinol. 2013;5(1):51-108.
63. Aranow C. Vitamin D and the immune system. J Investig Med. 2011;59(6):881-6.
64. Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311(5768):1770-3.
65. Nonn L, Peng L, Feldman D, Peehl DM. Inhibition of p38 by vitamin D reduces interleukin-6 production in prostate cancer cells. J Steroid Biochem Mol Biol. 2006;99(4-5):223-33.
66. Krishnan AV, Feldman D. Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annu Rev Pharmacol Toxicol. 2011;51:311-36.
67. Chung I, Han G, Seshadri M, et al. Role of vitamin D in the pathogenesis and treatment of colorectal cancer. J Steroid Biochem Mol Biol. 2009;114(3-5):187-95.
68. Majewski S, Szmurło A, Marczak L, et al. Vitamin D and the cardiovascular system - the dose matters. Int J Mol Sci. 2018;19(12):3743.
69. Janssens K, Van de Vyver G, Depovere J, et al. Vitamin D deficiency is associated with advanced stage and grade of prostate cancer at diagnosis. Prostate. 2015;75(13):1468-76.
70. Larkin O, Hussain K, Britton RG, et al. Antitumour activity of the vitamin D analogue EB 1089 in a xenograft model of metastatic prostate cancer. Anticancer Res. 2001;21(1A):23-8.
71. Correale PC, Ysrraelit MC, Shoshkes DA. The Role of Vitamin D in Prostate Cancer. Anticancer Agents Med Chem. 2016;16(4):454-62.
72. Ordóñez-Morán P, Larriba MJ, Palmer HG, Muñoz A. Rho GTPases and protein tyrosine phosphatases: potential players in the anti-tumour effects of vitamin D. Biochim Biophys Acta. 2008;1785(1):1-19.
73. Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis: Serum vitamin D and colorectal cancer risk. Eur J Cancer. 2011;47(1):116-24.
74. Gilbert R, Martin RM, Beynon J, Harris S, Savovic J, Dunlop MG. Association between low serum 25-hydroxyvitamin D and colorectal cancer risk: a systematic review and meta-analysis. Eur J Cancer. 2012;48(17):3214-28.
75. Wacker M, Holick MF. Sunlight and Vitamin D: A global perspective for health. Dermatoendocrinol. 2013;5(1):51-108.
76. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911-30.
77. Fedirko V, Bostick RM, Goodman M, et al. Effects of vitamin D and calcium supplementation on cancer incidence and mortality. Br J Cancer. 2017;116(4):447-460.
78. Gandini S, Boniol M, Haug U, et al. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer. 2011;128(6):1414-24.
79. Carr AC, Frei B. Toward a new recommended dietary allowance for vitamin C based on antioxidant and health effects in humans. Am J Clin Nutr. 1999;69(6):1086-107.
80. Padayatty SJ, Katz A, Wang Y, et al. Vitamin C as an antioxidant: evaluation of its role in disease prevention. J Am Coll Nutr. 2003;22(1):18-35.
81. Wintergerst ES, Maggini S, Hornig DH. Immune-enhancing role of vitamin C and zinc and effect on clinical conditions. Ann Nutr Metab. 2006;50(2):85-94.
82. Jariwalla RJ, Harakeh S. Antiviral and immunomodulatory activities of ascorbic acid. Subcell Biochem. 1996;25:215-31.
83. Boyera N, Galey I, Bernard BA. Effect of vitamin C and its derivatives on collagen synthesis and cross-linking by normal human fibroblasts. Int J Cosmet Sci. 1998;20(3):151-8.
84. Murad S, Grove D, Lindberg KA, Reynolds G, Sivarajah A, Pinnell SR. Regulation of collagen synthesis by ascorbic acid. Proc Natl Acad Sci U S A. 1981;78(5):2879-82.
85. Lutsenko EA, Carcamo JM, Golde DW. Vitamin C prevents DNA mutation induced by oxidative stress. J Biol Chem. 2002;277(19):16895-9.
86. Kiyose C, Kagawa Y, Ukai Y, et al. Long-term dietary ingestion of high vitamin C and vitamin E mixtures protects ovaries from age-related oxidative stress and delays age-associated ovarian failure in senescence accelerated mice. J Clin Biochem Nutr. 2009;45(3):287-92.
87. Chen Q, Espey MG, Krishna MC, et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci U S A. 2005;102(38):13604-9.
88. Du J, Martin SM, Levine M, et al. Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer. Clin Cancer Res. 2010;16(2):509-20.
89. Campbell EJ, Dachs GU, Vissers MCM. (2019). Vitamin C and Immune Function. Nutrients. 11(11), 2662.
90. Carr AC, Maggini S. Vitamin C and Immune Function. Nutrients. 2017;9(11):1211.
91. Mikirova N, Ichim TE, Riordan NH. Intravenous vitamin C in the supportive care of cancer patients: a review and rational approach. J Transl Med. 2013;11:189.
92. Alexander J, Cox R, Duconge J, et al. Oral administration of high-dose ascorbic acid inhibits tumor growth in BALB/c mice implanted with sarcoma 180 cancer cells. J Manipulative Physiol Ther. 2007;30(6):403-8.
93. Ashino H, Shimamura M, Nakajima H, Dombou M, Kawanaka S, Kambayashi J. Novel function of ascorbic acid as an angiogenic factor. Angiogenesis. 2003;6(1):25-32.
94. Mikirova N, Casciari JJ, Riordan NH. Ascorbate inhibition of angiogenesis in aortic rings ex vivo and subcutaneous Matrigel plugs in vivo. J Angiogenes Res. 2010;2:13.
95. Padayatty SJ, Sun H, Wang Y, et al. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med. 2004;140(7):533-7.
96. Levine M, Conry-Cantilena C, Wang Y, et al. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended intravenous dose limit. Proc Natl Acad Sci U S A. 1996;93(8):3704-9.
97. Jomova K, Valko M. Advances in metal-induced oxidative stress and human disease. Toxicology. 2011;283(2-3):65-87.
98. Flora SJ, Mittal M, Mehta A. Heavy metal induced oxidative stress & its possible reversal by chelation therapy. Indian J Med Res. 2008;128(4):501-23.
99. Hartwig A. Metal interaction with redox regulation: An integrating concept in metal carcinogenesis? Free Radic Biol Med. 2013;55:63-72.
100. Beyersmann D, Hartwig A. Carcinogenic metal compounds: recent insight into molecular and cellular mechanisms. Arch Toxicol. 2008;82(8):493-512.
101. Herceg Z, Herceg Z. Epigenetics and cancer: towards an evaluation of the impact of environmental and dietary factors. Mutagenesis. 2010;25(4):371-83.
102. Alegría-Torres JA, Baccarelli A, Bollati V. Epigenetics and lifestyle. Epigenomics. 2011;3(3):267-77.
103. Casanueva FF, Burguera B, Muruais C, Dieguez C. Acute administration of heavy metals to rats alters hypothalamic-pituitary function. Neuroendocrinology. 1989;50(1):105-11.
104. Heath JC, Khan MA. The Lead and Cadmium Content of Some Pakistani Cigarettes. J Pak Med Assoc. 1973;23(11):329-331.
105. Anderson ME. Chelation therapy for environmental and heavy metal poisoning. J Adv Med. 1987;1(1):34-40.
106. Flora SJ, Pachauri V. Chelation in metal intoxication. Int J Environ Res Public Health. 2010;7(7):2745-88.